Cargando…
Evaluation of the Novel Sepsis Biomarker Host-Derived Delta-like Canonical Notch Ligand 1—A Secondary Analysis of 405 Patients Suffering from Inflammatory or Infectious Diseases
Sepsis is defined as organ failure caused by dysregulated host response to infection. While early antibiotic treatment in patients with acute infection is essential, treating non-infectious patients must be avoided. Current guidelines recommend procalcitonin (PCT) to guide discontinuation of antibio...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252395/ https://www.ncbi.nlm.nih.gov/pubmed/37298115 http://dx.doi.org/10.3390/ijms24119164 |
_version_ | 1785056160977518592 |
---|---|
author | Hölle, Tobias Rehn, Patrick Leventogiannis, Konstantinos Kotsaki, Antigone Kanni, Theodora Antonakos, Nikolaos Psarrakis, Christos Damoraki, Georgia Schenz, Judith Schmitt, Felix C. F. Uhle, Florian Weigand, Markus A. Giamarellos-Bourboulis, Evangelos J. Dietrich, Maximilian |
author_facet | Hölle, Tobias Rehn, Patrick Leventogiannis, Konstantinos Kotsaki, Antigone Kanni, Theodora Antonakos, Nikolaos Psarrakis, Christos Damoraki, Georgia Schenz, Judith Schmitt, Felix C. F. Uhle, Florian Weigand, Markus A. Giamarellos-Bourboulis, Evangelos J. Dietrich, Maximilian |
author_sort | Hölle, Tobias |
collection | PubMed |
description | Sepsis is defined as organ failure caused by dysregulated host response to infection. While early antibiotic treatment in patients with acute infection is essential, treating non-infectious patients must be avoided. Current guidelines recommend procalcitonin (PCT) to guide discontinuation of antibiotic treatment. For initiation of therapy, there is currently no recommended biomarker. In this study, we evaluated Host-Derived Delta-like Canonical Notch Ligand 1 (DLL1), a monocyte membrane ligand that has shown promising results in differentiating infectious from non-infectious critically ill patients. Soluble DLL1 levels were measured in plasma samples of six different cohorts. The six cohorts comprise two cohorts with non-infectious inflammatory auto-immune diseases (Hidradenitis Suppurativa, Inflammatory Bowel Disease), one cohort of bacterial skin infection, and three cohorts of suspected systemic infection or sepsis. In total, soluble DLL1 plasma levels of 405 patients were analyzed. Patients were divided into three groups: inflammatory disease, infection, and sepsis (defined according to the Sepsis-3 definition), followed by the evaluation of its diagnostic performance via Area Under the Receiver Operating Characteristics (AUROC) analyses. Patients of the sepsis group showed significantly elevated plasma DLL1 levels compared to patients with uncomplicated infections and sterile inflammation. However, patients with infections had significantly higher DLL1 levels than patients with inflammatory diseases. Diagnostic performance was evaluated and showed better performance for DLL1 for the recognition of sepsis (AUC: 0.823; CI 0.731–0.914) than C-reactive protein (AUC 0.758; CI 0.658–0.857), PCT (AUC 0.593; CI 0.474–0.711) and White Blood Cell count (AUC 0.577; CI 0.46–0.694). DLL1 demonstrated promising results for diagnosing sepsis and was able to differentiate sepsis from other infectious and inflammatory diseases. |
format | Online Article Text |
id | pubmed-10252395 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102523952023-06-10 Evaluation of the Novel Sepsis Biomarker Host-Derived Delta-like Canonical Notch Ligand 1—A Secondary Analysis of 405 Patients Suffering from Inflammatory or Infectious Diseases Hölle, Tobias Rehn, Patrick Leventogiannis, Konstantinos Kotsaki, Antigone Kanni, Theodora Antonakos, Nikolaos Psarrakis, Christos Damoraki, Georgia Schenz, Judith Schmitt, Felix C. F. Uhle, Florian Weigand, Markus A. Giamarellos-Bourboulis, Evangelos J. Dietrich, Maximilian Int J Mol Sci Article Sepsis is defined as organ failure caused by dysregulated host response to infection. While early antibiotic treatment in patients with acute infection is essential, treating non-infectious patients must be avoided. Current guidelines recommend procalcitonin (PCT) to guide discontinuation of antibiotic treatment. For initiation of therapy, there is currently no recommended biomarker. In this study, we evaluated Host-Derived Delta-like Canonical Notch Ligand 1 (DLL1), a monocyte membrane ligand that has shown promising results in differentiating infectious from non-infectious critically ill patients. Soluble DLL1 levels were measured in plasma samples of six different cohorts. The six cohorts comprise two cohorts with non-infectious inflammatory auto-immune diseases (Hidradenitis Suppurativa, Inflammatory Bowel Disease), one cohort of bacterial skin infection, and three cohorts of suspected systemic infection or sepsis. In total, soluble DLL1 plasma levels of 405 patients were analyzed. Patients were divided into three groups: inflammatory disease, infection, and sepsis (defined according to the Sepsis-3 definition), followed by the evaluation of its diagnostic performance via Area Under the Receiver Operating Characteristics (AUROC) analyses. Patients of the sepsis group showed significantly elevated plasma DLL1 levels compared to patients with uncomplicated infections and sterile inflammation. However, patients with infections had significantly higher DLL1 levels than patients with inflammatory diseases. Diagnostic performance was evaluated and showed better performance for DLL1 for the recognition of sepsis (AUC: 0.823; CI 0.731–0.914) than C-reactive protein (AUC 0.758; CI 0.658–0.857), PCT (AUC 0.593; CI 0.474–0.711) and White Blood Cell count (AUC 0.577; CI 0.46–0.694). DLL1 demonstrated promising results for diagnosing sepsis and was able to differentiate sepsis from other infectious and inflammatory diseases. MDPI 2023-05-23 /pmc/articles/PMC10252395/ /pubmed/37298115 http://dx.doi.org/10.3390/ijms24119164 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hölle, Tobias Rehn, Patrick Leventogiannis, Konstantinos Kotsaki, Antigone Kanni, Theodora Antonakos, Nikolaos Psarrakis, Christos Damoraki, Georgia Schenz, Judith Schmitt, Felix C. F. Uhle, Florian Weigand, Markus A. Giamarellos-Bourboulis, Evangelos J. Dietrich, Maximilian Evaluation of the Novel Sepsis Biomarker Host-Derived Delta-like Canonical Notch Ligand 1—A Secondary Analysis of 405 Patients Suffering from Inflammatory or Infectious Diseases |
title | Evaluation of the Novel Sepsis Biomarker Host-Derived Delta-like Canonical Notch Ligand 1—A Secondary Analysis of 405 Patients Suffering from Inflammatory or Infectious Diseases |
title_full | Evaluation of the Novel Sepsis Biomarker Host-Derived Delta-like Canonical Notch Ligand 1—A Secondary Analysis of 405 Patients Suffering from Inflammatory or Infectious Diseases |
title_fullStr | Evaluation of the Novel Sepsis Biomarker Host-Derived Delta-like Canonical Notch Ligand 1—A Secondary Analysis of 405 Patients Suffering from Inflammatory or Infectious Diseases |
title_full_unstemmed | Evaluation of the Novel Sepsis Biomarker Host-Derived Delta-like Canonical Notch Ligand 1—A Secondary Analysis of 405 Patients Suffering from Inflammatory or Infectious Diseases |
title_short | Evaluation of the Novel Sepsis Biomarker Host-Derived Delta-like Canonical Notch Ligand 1—A Secondary Analysis of 405 Patients Suffering from Inflammatory or Infectious Diseases |
title_sort | evaluation of the novel sepsis biomarker host-derived delta-like canonical notch ligand 1—a secondary analysis of 405 patients suffering from inflammatory or infectious diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252395/ https://www.ncbi.nlm.nih.gov/pubmed/37298115 http://dx.doi.org/10.3390/ijms24119164 |
work_keys_str_mv | AT holletobias evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT rehnpatrick evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT leventogianniskonstantinos evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT kotsakiantigone evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT kannitheodora evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT antonakosnikolaos evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT psarrakischristos evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT damorakigeorgia evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT schenzjudith evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT schmittfelixcf evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT uhleflorian evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT weigandmarkusa evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT giamarellosbourboulisevangelosj evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases AT dietrichmaximilian evaluationofthenovelsepsisbiomarkerhostderiveddeltalikecanonicalnotchligand1asecondaryanalysisof405patientssufferingfrominflammatoryorinfectiousdiseases |